Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development

被引:3
作者
Kasudhan, Kripa Shanker [1 ]
Patial, Ajay [2 ]
Mehra, Nancy [2 ]
Attri, Savita Verma [2 ]
Malhotra, Pankaj [3 ]
Pattanaik, Smita [1 ]
Lad, Deepesh [3 ]
Patil, Amol N. [1 ]
机构
[1] PGIMER, Dept Pharmacol, Chandigarh, India
[2] PGIMER, Dept Pediat, Adv Pediat Ctr, Chandigarh, India
[3] PGIMER, Dept Clin Haematol & Med Oncol, Chandigarh, India
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2022年 / 1198卷
关键词
Carboxyethyl phosphoramide mustard; Hydroxy cyclophosphamide; Cyclophosphamide; Liquid chromatography mass spectrometry; Post transplant; HEMATOPOIETIC-CELL TRANSPLANTATION; CONDITIONING REGIMENS; LIVER TOXICITY; 4-HYDROXYCYCLOPHOSPHAMIDE; PHARMACOKINETICS; METABOLITE; QUANTITATION; BUSULFAN; MARROW;
D O I
10.1016/j.jchromb.2022.123228
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A novel method for simultaneous quantification of cyclophosphamide along with its two major metabolites namely 4-hydroxycyclophosphamide (HCy) and carboxyethyl phosphoramide mustard (CEPM) in a single sample run was demonstrated in the present study. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrument was used for analysis. Semicarbazide was used as a stabilizing agent for HCy whereas ifosfamide, hexamethyl phosphoramide mustard and deuterated CEPM were the internal standards for quantification of Cy, HCy and CEPM respectively. Chromatographic separation was achieved by Chromsystems C18 reverse-phase column (50 mm x 4.6 mm, particle size 3.2 mu m). The mobile phase was composed of eluent A (2 mM ammonium acetate in water with 2% formic acid) and eluent B (100 % acetonitrile). The flow rate was 1 ml/min. Linearity of the assay was assured in the range of 19.53 ng/ml to 10,000 ng/ml concentration in human plasma, which is adequate for pharmacokinetic studies of any dose Cy used clinically. The quality control(QC) accuracy was between 99.58% and 101.62%, 97.85% to 103.53% and 99.64% to 100.10% for Cy, HCy and CEPM respectively. Precision limits for QC samples were between 3.9% and 9.4%, 5.2% to 8.9% and 1.8% to 9.2% respectively. The analytical method was validated in ten leukaemia patients undergoing haploidentical hematopoietic cell transplantation.
引用
收藏
页数:9
相关论文
共 22 条
[1]   Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N"-triethylenethiophosphoramide (thiotepa) and N,N′,N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry [J].
de Jonge, ME ;
van Dam, SM ;
Hillebrand, MJX ;
Rosing, H ;
Huitema, ADR ;
Rodenhuis, S ;
Beijnen, JH .
JOURNAL OF MASS SPECTROMETRY, 2004, 39 (03) :262-271
[2]   Clinical pharmacokinetics of cyclophosphamide [J].
de Jonge, ME ;
Huitema, ADR ;
Rodenhuis, S ;
Beijnen, JH .
CLINICAL PHARMACOKINETICS, 2005, 44 (11) :1135-1164
[3]   Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS) [J].
Ekhart, Corine ;
Gebretensae, Abadi ;
Rosing, Hilde ;
Rodenhuis, Sjoerd ;
Beijnen, Jos H. ;
Huitema, Alwin D. R. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 854 (1-2) :345-349
[4]   Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma [J].
Griskevicius, L ;
Meurling, L ;
Hassan, M .
THERAPEUTIC DRUG MONITORING, 2002, 24 (03) :405-409
[5]   Conditioning regimens for hematopoietic cell transplantation: one size does not fit all [J].
Gyurkocza, Boglarka ;
Sandmaier, Brenda M. .
BLOOD, 2014, 124 (03) :344-353
[6]   A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma [J].
Hall, O. Morgan ;
Peer, Cody J. ;
Fitzhugh, Courtney D. ;
Figg, William D. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2018, 1086 :56-62
[7]   The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite:: time interval influence on therapeutic efficacy and therapy-related toxicity [J].
Hassan, M ;
Ljungman, P ;
Ringdén, O ;
Hassan, Z ;
Öberg, G ;
Nilsson, C ;
Békassy, A ;
Bielenstein, M ;
Abdel-Rehim, M ;
Georén, S ;
Astner, L .
BONE MARROW TRANSPLANTATION, 2000, 25 (09) :915-924
[8]   T-cell modulation by cyclophosphamide for tumour therapy [J].
Hughes, Ellyn ;
Scurr, Martin ;
Campbell, Emma ;
Jones, Emma ;
Godkin, Andrew ;
Gallimore, Awen .
IMMUNOLOGY, 2018, 154 (01) :62-68
[9]  
Huitema A.D.R., J LIQ CHROMATOGR R T, V23
[10]   Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis [J].
Joy, Melanie S. ;
La, Mary ;
Wang, Jinzhao ;
Bridges, Arlene S. ;
Hu, Yichun ;
Hogan, Susan L. ;
Frye, Reginald F. ;
Blaisdell, Joyce ;
Goldstein, Joyce A. ;
Dooley, Mary Anne ;
Brouwer, Kim L. R. ;
Falk, Ronald J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (03) :445-455